Total Payments
$14,393
2024 Payments
$1,968
Companies
31
Transactions
646
Medicare Patients
13,212
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$14,364 (99.8%)
Education$28.86 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,364 | 643 | 99.8% |
| Education | $28.86 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,974 | 101 | $0 (2024) |
| Amgen Inc. | $1,970 | 77 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,708 | 76 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,395 | 61 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,113 | 61 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,103 | 40 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,001 | 46 | $0 (2024) |
| PFIZER INC. | $776.60 | 36 | $0 (2024) |
| Merck Sharp & Dohme LLC | $691.09 | 31 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $550.37 | 24 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,968 | 76 | Novartis Pharmaceuticals Corporation ($277.67) |
| 2023 | $1,788 | 76 | Novartis Pharmaceuticals Corporation ($312.33) |
| 2022 | $2,209 | 98 | Janssen Pharmaceuticals, Inc ($312.21) |
| 2021 | $1,690 | 76 | Janssen Pharmaceuticals, Inc ($299.78) |
| 2020 | $920.72 | 43 | Novartis Pharmaceuticals Corporation ($221.25) |
| 2019 | $1,772 | 86 | Novartis Pharmaceuticals Corporation ($267.01) |
| 2018 | $1,765 | 80 | SANOFI-AVENTIS U.S. LLC ($315.03) |
| 2017 | $2,280 | 111 | Amgen Inc. ($477.07) |
All Payment Transactions
646 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Philips North America LLC | (K95) ECC Solutions (Device) | Food and Beverage | Cash or cash equivalent | $25.20 | General |
| Category: Medical Device | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.02 | General |
| Category: Cardiovascular | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $26.48 | General |
| Category: Medical Device | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $33.78 | General |
| Category: Cardiovascular | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: DIABETES | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/07/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $30.84 | General |
| Category: Medical Device | ||||||
| 11/01/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Cardiac Rhythm Management | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $33.27 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/16/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $30.45 | General |
| Category: Medical Device | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/23/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $15.82 | General |
| Category: Medical Device | ||||||
| 09/19/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/18/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $15.86 | General |
| Category: Coronary | ||||||
| 09/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $39.75 | General |
| Category: Cardiovascular | ||||||
| 09/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 3,260 | 5,449 | $2.6M | $362,730 |
| 2022 | 19 | 3,418 | 5,731 | $2.9M | $405,914 |
| 2021 | 17 | 3,474 | 5,858 | $2.9M | $411,103 |
| 2020 | 17 | 3,060 | 5,255 | $2.3M | $294,597 |
Total Patients
13,212
Total Services
22,293
Medicare Billing
$1.5M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 732 | 1,582 | $870,100 | $177,851 | 20.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 397 | 409 | $791,415 | $72,517 | 9.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 346 | 448 | $168,000 | $34,074 | 20.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 868 | 2,027 | $293,915 | $25,939 | 8.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 118 | 118 | $117,646 | $17,496 | 14.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 128 | 128 | $78,464 | $8,721 | 11.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 39 | 39 | $68,484 | $6,935 | 10.1% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 67 | 73 | $86,870 | $4,659 | 5.4% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 42 | 61 | $34,404 | $3,067 | 8.9% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 28 | 35 | $24,150 | $2,526 | 10.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 131 | 132 | $15,840 | $2,459 | 15.5% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 131 | 132 | $10,428 | $1,640 | 15.7% |
| 93289 | Evaluation of single, dual, or multiple lead implantable defibrillator system | Office | 2023 | 12 | 20 | $13,840 | $1,322 | 9.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 53 | 53 | $7,897 | $1,080 | 13.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 66 | 87 | $1,796 | $730.80 | 40.7% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 26 | 27 | $11,880 | $610.74 | 5.1% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 44 | 44 | $4,708 | $510.28 | 10.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 16 | 17 | $2,788 | $395.76 | 14.2% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 16 | 17 | $1,819 | $194.39 | 10.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 738 | 1,683 | $925,650 | $191,231 | 20.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 441 | 450 | $870,750 | $83,560 | 9.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 341 | 426 | $159,750 | $34,884 | 21.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 894 | 2,107 | $305,515 | $27,676 | 9.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 164 | 164 | $163,508 | $26,507 | 16.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 55 | 55 | $96,580 | $10,219 | 10.6% |
About Dr. Valery Kuznetsov, M.D
Dr. Valery Kuznetsov, M.D is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841218039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Valery Kuznetsov, M.D has received a total of $14,393 in payments from pharmaceutical and medical device companies, with $1,968 received in 2024. These payments were reported across 646 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($14,364).
As a Medicare-enrolled provider, Kuznetsov has provided services to 13,212 Medicare beneficiaries, totaling 22,293 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 07/17/2006
- Last Updated 07/31/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1841218039
Products in Payments
- XARELTO (Drug) $1,679
- ELIQUIS (Drug) $1,649
- ENTRESTO (Drug) $1,389
- Repatha (Biological) $1,332
- MULTAQ (Drug) $727.38
- FARXIGA (Drug) $707.35
- VERQUVO (Drug) $691.09
- Corlanor (Drug) $637.13
- JARDIANCE (Drug) $605.98
- LEQVIO (Drug) $585.35
- PRADAXA (Drug) $394.82
- PRALUENT ALIROCUMAB INJECTION (Biological) $388.24
- PRALUENT (Drug) $375.97
- Edarbi (Drug) $366.80
- BRILINTA (Drug) $292.32
- CAMZYOS (Drug) $287.86
- Veltassa (Drug) $213.50
- Kerendia (Drug) $211.26
- CHANTIX (Drug) $210.63
- NEXLETOL (Drug) $164.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Cardiovascular Disease $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Cardiovascular Disease $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Cardiovascular Disease $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Cardiovascular Disease $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Cardiovascular Disease $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799
Cardiovascular Disease $225,799